Table 1.

Vamorolone Dose-Dependent Change From Baseline for Motor Endpoints Over 48-Week Treatment (mITT-2 Population)

End point (n for vamorolone 6 vs vamorolone 2 mg/kg/d)	Vamorolone 6 mg/kg/d LSM (SE) vs vamorolone 2 mg/kg/d LSM (SE)	LSM difference (SE)	LSM difference (95% CI)	p Value
TTSTAND velocity (rises/s) (27 vs 28)	0.0446 (0.0138) vs −0.0053 (0.0135)	0.0500 (0.0186)	0.0126 to 0.0874	0.010
6MWD (m) (19 vs 21)	49.6823 (12.5359) vs 14.9190 (12.3367)	34.7634 (17.0194)	0.4506 to 69.0761	0.047
TTCLIMB velocity (tasks/s) (24 vs 23)	0.1120 (0.0169) vs 0.0589 (0.0172)	0.0531 (0.0238)	0.0052 to 0.1010	0.031
TTRW velocity (m/s) (24 vs 24)	0.2519 (0.0747) vs 0.1544 (0.0746)	0.0976 (0.1032)	−0.1099 to 0.3051	0.349
NSAA (score) (24 vs 23)	3.0834 (0.8287) vs 2.5933 (0.8259)	0.4901 (1.1404)	−1.8041 to 2.7843	0.670

Abbreviations: 6MWD = 6-minute walk distance; LSM = least squares mean; mITT-2 = modified intention to treat–2; NSAA = North Star Ambulatory Assessment; SE = standard error; TTCLIMB = time to climb 4 steps; TTRW = time to run/walk 10 m; TTSTAND = time to stand from supine.